Brief: Biogen Outlook FY Adjusted EPS $14.25 To $15.25 Vs IBES Estimate $15.04
29/04/2026 11:00
April 29 (Reuters) - Biogen Inc BIIB.O: Q1 ADJUSTED EPS $3.57 VERSUS. IBES ESTIMATE $2.77 Q1 REVENUE $2.48 BILLION VERSUS. IBES ESTIMATE $2.25 BILLION OUTLOOK FY ADJUSTED EPS $14.25 TO $15.25 VERSUS IBES ESTIMATE $15.04 FY GUIDANCE INCLUDES ABOUT $1 IMPACT PER SHARE FROM ACQUIRED IPR&D CHARGES OUTLOOK 2026 REVENUE DECLINE BY MID-SINGLE DIGIT PERCENTAGE FY2026 REVENUE VIEW $9.84 BILLION -- LSEG IBES DATA TO PROVIDE UPDATED 2026 GUIDANCE INCLUSIVE OF APELLIS WHEN IT REPORTS Q2 EARNINGS Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout